These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 23445611)

  • 41. Cyclopamine sensitizes TRAIL-resistant gastric cancer cells to TRAIL-induced apoptosis via endoplasmic reticulum stress-mediated increase of death receptor 5 and survivin degradation.
    Na YJ; Lee DH; Kim JL; Kim BR; Park SH; Jo MJ; Jeong S; Kim HJ; Lee SY; Jeong YA; Oh SC
    Int J Biochem Cell Biol; 2017 Aug; 89():147-156. PubMed ID: 28624529
    [TBL] [Abstract][Full Text] [Related]  

  • 42. APC selectively mediates response to chemotherapeutic agents in breast cancer.
    VanKlompenberg MK; Bedalov CO; Soto KF; Prosperi JR
    BMC Cancer; 2015 Jun; 15():457. PubMed ID: 26049416
    [TBL] [Abstract][Full Text] [Related]  

  • 43. WNT10B/β-catenin signalling induces HMGA2 and proliferation in metastatic triple-negative breast cancer.
    Wend P; Runke S; Wend K; Anchondo B; Yesayan M; Jardon M; Hardie N; Loddenkemper C; Ulasov I; Lesniak MS; Wolsky R; Bentolila LA; Grant SG; Elashoff D; Lehr S; Latimer JJ; Bose S; Sattar H; Krum SA; Miranda-Carboni GA
    EMBO Mol Med; 2013 Feb; 5(2):264-79. PubMed ID: 23307470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Targeting miRNAs associated with surface expression of death receptors to modulate TRAIL resistance in breast cancer.
    Zhu J; Zhou Q; Tan S
    Cancer Lett; 2016 Dec; 383(2):154-160. PubMed ID: 27693456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Novel strategies to target chemoresistant triple-negative breast cancer.
    Venkatesh J; Rishi AK; Reddy KB
    Genes Cancer; 2020 Dec; 11(3-4):95-105. PubMed ID: 33488948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.
    Eustace AJ; Conlon NT; McDermott MSJ; Browne BC; O'Leary P; Holmes FA; Espina V; Liotta LA; O'Shaughnessy J; Gallagher C; O'Driscoll L; Rani S; Madden SF; O'Brien NA; Ginther C; Slamon D; Walsh N; Gallagher WM; Zagozdzon R; Watson WR; O'Donovan N; Crown J
    BMC Cancer; 2018 Oct; 18(1):965. PubMed ID: 30305055
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting the glyoxalase pathway enhances TRAIL efficacy in cancer cells by downregulating the expression of antiapoptotic molecules.
    Taniguchi H; Horinaka M; Yoshida T; Yano K; Goda AE; Yasuda S; Wakada M; Sakai T
    Mol Cancer Ther; 2012 Oct; 11(10):2294-300. PubMed ID: 22784708
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Regulation of TRAIL receptor expression by β-catenin in colorectal tumours.
    Jalving M; Heijink DM; Koornstra JJ; Boersma-van Ek W; Zwart N; Wesseling J; Sluiter WJ; de Vries EG; Kleibeuker JH; de Jong S
    Carcinogenesis; 2014 May; 35(5):1092-9. PubMed ID: 24379239
    [TBL] [Abstract][Full Text] [Related]  

  • 49. OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer.
    De Toni EN; Thieme SE; Herbst A; Behrens A; Stieber P; Jung A; Blum H; Göke B; Kolligs FT
    Clin Cancer Res; 2008 Aug; 14(15):4713-8. PubMed ID: 18676739
    [TBL] [Abstract][Full Text] [Related]  

  • 50. MiR-519d impedes cisplatin-resistance in breast cancer stem cells by down-regulating the expression of MCL-1.
    Xie Q; Wang S; Zhao Y; Zhang Z; Qin C; Yang X
    Oncotarget; 2017 Mar; 8(13):22003-22013. PubMed ID: 28423543
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cisplatin-dependent upregulation of death receptors 4 and 5 augments induction of apoptosis by TNF-related apoptosis-inducing ligand against esophageal squamous cell carcinoma.
    Kondo K; Yamasaki S; Sugie T; Teratani N; Kan T; Imamura M; Shimada Y
    Int J Cancer; 2006 Jan; 118(1):230-42. PubMed ID: 16003725
    [TBL] [Abstract][Full Text] [Related]  

  • 52. FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling.
    Li Q; Ye L; Zhang X; Wang M; Lin C; Huang S; Guo W; Lai Y; Du H; Li J; Song L; Peng X
    Cancer Lett; 2017 Aug; 402():166-176. PubMed ID: 28602974
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination of Ad-sTRAIL with the chemotherapeutic drug cisplatin synergistically enhances their pro-apoptotic ability in human breast cancer cells.
    Liu X; Wang J; Wang H; Liu S; Liang Y; Lv Z; Zhou Q; Ding W
    Oncol Rep; 2013 Oct; 30(4):1913-9. PubMed ID: 23912708
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy.
    Litzenburger BC; Creighton CJ; Tsimelzon A; Chan BT; Hilsenbeck SG; Wang T; Carboni JM; Gottardis MM; Huang F; Chang JC; Lewis MT; Rimawi MF; Lee AV
    Clin Cancer Res; 2011 Apr; 17(8):2314-27. PubMed ID: 21177763
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Repeated treatment with subtoxic doses of TRAIL induces resistance to apoptosis through its death receptors in MDA-MB-231 breast cancer cells.
    Yoshida T; Zhang Y; Rivera Rosado LA; Zhang B
    Mol Cancer Res; 2009 Nov; 7(11):1835-44. PubMed ID: 19843632
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism.
    Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A
    Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681
    [TBL] [Abstract][Full Text] [Related]  

  • 57. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Smac mimetics in combination with TRAIL selectively target cancer stem cells in nasopharyngeal carcinoma.
    Wu MS; Wang GF; Zhao ZQ; Liang Y; Wang HB; Wu MY; Min P; Chen LZ; Feng QS; Bei JX; Zeng YX; Yang D
    Mol Cancer Ther; 2013 Sep; 12(9):1728-37. PubMed ID: 23699656
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
    Engel JB; Martens T; Hahne JC; Häusler SF; Krockenberger M; Segerer S; Djakovic A; Meyer S; Dietl J; Wischhusen J; Honig A
    Anticancer Drugs; 2012 Apr; 23(4):426-36. PubMed ID: 22314264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures.
    Kabos P; Finlay-Schultz J; Li C; Kline E; Finlayson C; Wisell J; Manuel CA; Edgerton SM; Harrell JC; Elias A; Sartorius CA
    Breast Cancer Res Treat; 2012 Sep; 135(2):415-32. PubMed ID: 22821401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.